LENZ

In the past six months, LENZ Therapeutics' stock has been significantly impacted by several events. In May 2026, Q1 2026 financial results showed product revenues of $1.7 million from VIZZ, a 19% increase over Q4 2025. A new telehealth prescribing option for VIZZ was launched in July 2026. However, in August 2026, the stock price fell sharply after Q2 2026 financial results revealed total revenue of $5.5 million, with $3.8 million from one-time global licensing milestones and flat organic product sales for VIZZ at $1.73 million, showing only 9% quarter-over-quarter volume growth. Following this, on August 12, 2026, Bank of America downgraded LENZ stock from "Buy" to "Neutral" and lowered its price target from $31.00 to $7.00, citing a significantly slower-than-expected commercial launch for VIZZ. This led to an investigation by Pomerantz LLP into potential securities fraud. The stock has experienced a significant decline, with a 6-month change of -57.75% as of August 2025.